511 related articles for article (PubMed ID: 15385107)
1. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
3. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
4. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
[TBL] [Abstract][Full Text] [Related]
6. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C
Oncology; 2005; 69(5):363-71. PubMed ID: 16319507
[TBL] [Abstract][Full Text] [Related]
11. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
[TBL] [Abstract][Full Text] [Related]
12. [Imatinib].
Urabe A
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Holdhoff M; Kreuzer KA; Appelt C; Scholz R; Na IK; Hildebrandt B; Riess H; Jordan A; Schmidt CA; Van Etten RA; Dörken B; le Coutre P
Blood Cells Mol Dis; 2005; 34(2):181-5. PubMed ID: 15727903
[TBL] [Abstract][Full Text] [Related]
14. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
[TBL] [Abstract][Full Text] [Related]
15. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
[TBL] [Abstract][Full Text] [Related]
16. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
17. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
18. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
20. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
